Emerging research suggests that GLP-1 medications such as Ozempic and Wegovy, widely used for diabetes and weight loss, may also help lower the risk of cancer diagnosis and recurrence, according to a Texas-based breast cancer surgeon. This would mark a significant expansion of the drugs' known benefits, potentially offering protection against one of the leading causes of death worldwide beyond their established roles in metabolic health.

Dr Loren Rourke, a board-certified breast cancer surgeon, author and speaker, said growing evidence points to glucagon-like peptide-1 (GLP-1) drugs being linked to reduced rates of cancer recurrence, citing relevant findings from recent studies. While the article does not detail the full body of research or specific statistical outcomes, it frames the potential link as a promising area for further investigation into how these already popular medications might offer wider health benefits.